Table 1 The Characteristics and Newcastle–Ottawa scale score of studies included in the meta-analysis
Study | Country/Ethnicity | SNPs evaluated | No. of patients | Mean age ± SD | Protocol | Study design | Genotyping | HWE | Outcomes* | NOS scores |
|---|---|---|---|---|---|---|---|---|---|---|
Lledó, 2019 [18] | Spain/Caucasian | AMH/ AMHR2 | 124 | 23.9 ± 3.5 | GnRH-A | prospective | PCR | Yes | 1.2.3 | 6 |
Wu, 2019 [21] | China/Asian | AMH/AMHR2 | 635 | NA | GnRHa | prospective | PCR | Yes | 1.2.3.4.7 | 6 |
Lazaros, 2016 [17] | Greece/Caucasian | AMHR2 | 300 | 28–38 | GnRHa | prospective | PCR | Yes | 3. 4. | 7 |
Cerra, 2016 [15] | UK/multiple | AMH/AMHR2 | 603 | NA | GnRHa/GnRH-A | prospective | TaqMan | No metion | 2. 3. 5. 8 | 6 |
Peluso, 2015 [19] | Brazil | AMH/AMHR2 | 186 | 32.5 ± 3.5 | GnRH-A | prospective | TaqMan | Yes | 3. 6. 7. 8. | 6 |
Wang, 2015 [20] | China/Asian | AMH | 122 | NA | GnRHa | retrospective | PCR | Yes | 3 | 7 |
Karagiorga, 2015 [16] | Greece | AMH/AMHR2 | 151 | 36 ± 5 | GnRHa/GnRH-A | prospective | PCR | Yes | 1. 2. 3. 4. | 7 |